SR9009, also known as Stenabolic, is a synthetic compound that has been studied for its potential effects on the regulation of circadian rhythms and metabolism. It is not a Selective Androgen Receptor Modulator (SARM) but rather belongs to a different class of compounds known as Rev-Erb agonists.
SR9009 is believed to activate Rev-Erb proteins, which play a role in regulating various physiological processes, including the body's circadian rhythm (the internal biological clock) and metabolism. It has been studied in preclinical research for its potential impact on enhancing exercise performance, improving endurance, and influencing metabolic parameters.
As of my last knowledge update in January 2022, it's important to note that SR9009 is not approved for medical use in many countries, and its safety and long-term effects in humans are not well-established. Additionally, the use of SR9009 has been a subject of controversy, especially in sports and bodybuilding circles.
If you are considering the use of SR9009 or any similar compound, it is crucial to consult with a healthcare professional. The use of such substances without proper guidance can pose risks to health, and their regulatory status may vary by jurisdiction. Stay informed about the latest scientific research and regulatory information related to SR9009, and prioritize your health and safety
Product Name: | SR9009 |
Synonyms: | SR9009 sarms,whnohe_lucy(at)163.com;Ethyl 3-[[[(4-chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-1-pyrrolidinecarboxylate;CS-2027;SR9009 Powder whnohe_carolineat163.com;Stenabolic (SR9009);SR9009;3-[[[(4-Chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-1-pyrrolidinecarboxylic acid ethyl ester;STENABOLIC |
CAS: | 1379686-30-2 |
MF: | C20H24ClN3O4S |
MW: | 437.94 |
EINECS: | 1592732-453-0 |
Product Categories: | SARMs(Selective androgen receptor modulator);1379686-30-2 |
Description | SR-9009 is an agonist at nuclear receptor Rev-ErbA. Greatly diminishes VILI-induced lung edema, inflammatory cell infiltration and TNFα production in a rat lung injury model. SR-9009 suppresses atherosclerosis in a mouse model. Specifically lethal to cancer cells and oncogene-induced senescent cells with no effect on the viability of normal cells or tissues. Disrupts pain associated with osteoarthritis by reducing BMAL1 expression in bmal1f/fNav1.8CreERT mice. |
Uses | SR 9009 is a synthetic REV-ERB agonist that regulates circadian behavior and metabolism; has potential use in the treatment of sleep disorders and metabolic diseases. It is a lead compound for a new class of cancer drugs associated with the body’s circadian clock. |